10 Best Affordable Healthcare Stocks to Buy Now

8. Novo Nordisk A/S (NYSE:NVO)

Forward P/E: 14.41

Number of Hedge Fund Holders: 50

Novo Nordisk A/S (NYSE:NVO) is one of the best affordable healthcare stocks to buy now. On December 22, Novo Nordisk A/S (NYSE:NVO) announced the FDA approval of the Wegovy^® pill, a once-daily oral semaglutide 25 mg, for long term weight management, excess body weight reduction, and reduction in the risk of major adverse cardiovascular events. The approval makes the Wegovy^® pill the first oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy approved for weight management.

In another development, Novo Nordisk A/S (NYSE:NVO) announced on December 18 the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for once-weekly CagriSema, which is a cagrilintide 2.4 mg and semaglutide 2.4 mg injection, for use with increased physical activity and a reduced-calorie diet for the reduction of excess body weight and maintenance of long term weight reduction in adults with obesity of overweight. CagriSema is a fixed-dose combination of a long-acting amylin analogue, cagrilintide 2.4 mg, and the GLP-1 receptor agonist, semaglutide 2.4 mg.

Management reported that if CagriSema  is approved, it would become the first injectable GLP-1 receptor agonist and amylin analogue combination treatment. It added that adults with obesity or overweight, with at least one obesity-related complication, lost an average of 23% body weight after taking CagriSema in the REDEFINE 1 phase 3 trial when evaluating the treatment effect if all patients stayed on treatment.

Novo Nordisk A/S (NYSE:NVO) further reported that the FDA is anticipated to review the CagriSema application in 2026, with the company continuing to build on its 100-year-plus legacy of innovation and science with potential new treatments in the obesity sphere.

Novo Nordisk A/S (NYSE:NVO) is a global healthcare company specializing in diabetes care. It develops, discovers, manufactures, and markets pharmaceutical products. Its operations are divided into two business segments: biopharmaceuticals and diabetes and obesity care. The latter segment covers GLP-1, insulin, and other protein-related products.